Ibogaine Evidence Base: 2026

No. As of October 12, 2026, ibogaine is not FDA-approved for any indication and remains a Schedule I controlled substance in the United States. The first US IND for an ibogaine-class compound (DemeRx's oral noribogaine for alcohol use disorder) was accepted in April 2026 but has not opened enrollment, and the $100 million Texas IMPACT programme is in protocol development. Kentucky's 2023 proposal to direct $42 million of opioid settlement funds into ibogaine research was shelved in early 2024, though the state legislature revisited the idea in 2026. Any FDA approval, if and when it occurs, would depend entirely on trial outcomes and agency review; both parent ibogaine and noribogaine remain investigational, and no specific indication, formulation, or approval sequence can be assumed today.

Three converging signals. (1) Acute withdrawal reduction: Mash 2018 (n=191), Brown & Alper 2018 (n=30), Davis 2017 (n=88) all report rapid, significant reductions in withdrawal severity. (2) Durability: in Brown & Alper, 50% reported no opioid use in the prior 30 days at one-month follow-up, with drug-use improvements sustained through 12 months; in Davis, 41% reported sustained abstinence of more than six months. (3) Mechanism: multiple animal and human studies show ibogaine remodels opioid receptor expression and resets dopaminergic tone. The signal is consistent across designs, populations, and decades. The remaining gap is a controlled US trial; the first US IND was accepted in April 2026 and the funded Texas IMPACT programme is being built to close exactly that gap.

Because it was the first US-designed, well-monitored prospective study in a defined population (special-operations veterans with TBI and PTSD) using the magnesium-protection paradigm. Effect sizes were large (around 88% average reduction in PTSD symptoms at one month, with comparable improvements in depression and anxiety) and there were no serious cardiac events. It established that with proper screening and magnesium pre-treatment, the cardiac risk that limited earlier programmes can be substantially mitigated, and follow-up neuroimaging analyses from the same cohort are now appearing in the literature (Nature Mental Health, 2025; iScience, 2026). Twelve-month symptom-durability outcomes have not yet been published.

The risk is real but quantifiable. Glue 2016 established the noribogaine PK profile and showed dose-dependent QTc prolongation. Knuijver 2022 refined the dose-response curve in opioid-maintained patients. Across the credentialed clinical literature with continuous telemetry and proper screening, serious cardiac events (torsades de pointes, sudden cardiac death) are reported as uncommon. See Alper et al. (J Forensic Sci 2012) and the Brown & Alper 2018 long-term cohort for documented incidence rates. The bulk of reported deaths in the older literature involved unscreened patients, supratherapeutic dosing, undisclosed co-medications, or settings without telemetry. Magnesium pre-treatment, electrolyte optimisation, CYP2D6 phenotyping, and 72-96 hour telemetry are the four pillars of modern cardiac safety.

Psilocybin and MDMA have stronger Phase 3 RCT data for major depressive disorder and PTSD respectively, and both are further along the FDA pathway. However, neither has the acute withdrawal-suppression effect that ibogaine demonstrates for opioid use disorder. Ibogaine occupies a distinctive therapeutic niche: among published psychedelic and atypical psychoplastogen agents we are aware of, it is the one most consistently described in the peer-reviewed literature as combining acute opioid-withdrawal suppression, modulation of opioid receptor signalling, and a sustained psychotherapeutic state in a single agent (see Brown & Alper 2018; Mash 2018; Davis 2017). We do not claim it is the sole molecule with any individual one of those effects. The three are not competitors. They are tools for different jobs. See our comparison pages for details.

Several major questions remain. (1) Optimal dose-response curves for non-opioid indications (depression, PTSD without TBI, alcohol use disorder) are still being mapped. (2) The relative therapeutic contribution of parent ibogaine versus the noribogaine metabolite is debated. DemeRx's Phase 2 trial of noribogaine alone will help. (3) Long-term outcome data beyond 12 months is sparse; multi-year follow-up cohorts are now being assembled. (4) Predictive biomarkers for treatment response are not yet validated. (5) The role of integration therapy intensity in outcome durability needs head-to-head comparison.

Our protocol incorporates every safety signal the published literature flags: pre-treatment cardiac screening (12-lead EKG, echocardiogram, comprehensive metabolic panel), magnesium pre-loading per the Stanford 2024 paradigm, CYP2D6 phenotyping when indicated, electrolyte optimisation to potassium >4.0 and magnesium >2.0, continuous telemetry from pre-medication through 72-96 hour noribogaine clearance, weight-banded and CYP2D6-adjusted dosing, ibogaine TA boosters during onsite medication tapers, and structured integration therapy post-treatment. We are not a research site, but every published safety and outcome signal we know of is built into the protocol.

Our most-tracked metric is onsite-taper completion: across our admitted SSRI/SNRI/benzodiazepine/Z-drug cohort, 98% of patients complete the supervised onsite taper, clear protocol-defined safety thresholds, and proceed to the ibogaine HCl flood dose without restarting their pre-arrival medication. This is drawn from internal admissions-to-flood-dose tracking and is available to referring clinicians and prescribing physicians on request. It is a taper-completion metric only. It is not a long-term remission rate, not an abstinence rate, and not a measure of sustained recovery. Long-term durability (remission, abstinence, relapse-free intervals) is a separate question still being studied by the Phase 2 / 3 trials underway. We track follow-up outcomes and intend to publish once the cohort and methodology can support a defensible peer-reviewed report.

Tabernanthe iboga root bark contains more than a dozen indole alkaloids (ibogaine, ibogamine, ibogaline, tabernanthine, tabernanthinine, ibogaminol, voacangine, coronaridine, conopharyngine, iboxygaine, ibogainoxine, and noribogaine precursors among others). The total-alkaloid (TA) preparation captures the receptor pharmacology of the entire family (serotonergic, GABAergic, opioidergic, NMDA) at sub-psychoactive doses. No single-molecule preparation reproduces the multi-receptor coverage that makes onsite SSRI / benzodiazepine bridging tolerable. Pharmaceutical-grade ibogaine HCl isolates one molecule and is appropriate for the flood dose itself. We invite correction from any facility delivering this protocol. To our knowledge, based on a review of publicly listed ibogaine programs and patient referral histories, MindScape is the only North American facility currently delivering full-spectrum TA-bridged onsite tapers under continuous cardiac telemetry, and we will update this page if another facility brings the same protocol online. See Mash 2018 and Glue 2016 for the most relevant published pharmacokinetic data on the parent alkaloid and noribogaine.

Two convergent mechanisms in the published literature. (1) Ibogaine upregulates glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area, with downstream reductions in self-administration of multiple substances of abuse in animal models. He et al. (J Neurosci 2005) is the foundational paper. (2) Ibogaine and noribogaine increase brain-derived neurotrophic factor (BDNF) signalling and 5-HT2A-mediated dendritic spine growth in cortical neurons, the same mechanism implicated in psilocybin and ketamine antidepressant effects (Marton et al., Front Pharmacol 2019; Inserra et al., Front Synaptic Neurosci 2021). The 7-14 day post-flood window is therefore a pharmacologically defined neuroplastic window. Our aftercare protocol is built around it: integration therapy, sleep-architecture restoration, and structured psychiatric follow-up. We describe this as neurorestoration, supported by published animal and human-tissue data, and we do not over-promise long-term outcomes that have not yet been confirmed in Phase 3 trials.

Full citations and DOI links are maintained at our research hub at /ibogaine-research-hub. We update it monthly when new peer-reviewed work appears. For active clinical trials, see our /ibogaine-clinical-trials-2026 page, which mirrors the relevant ClinicalTrials.gov registrations. For the cardiac literature specifically, see /ibogaine-cardiac-screening which footnotes the underlying papers. We do not include preprints, conference abstracts, or unpublished case reports in the main evidence map, only peer-reviewed work or pre-registered trials.